Begoña Mellado

Also affiliated with Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial”.

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

The Lancet(2024)10.1016/s0140-6736(24)01653-2

N/A

4.3DataRank · unranked

287 citations

Daniel Castellano, Ken Herrmann, Johann S. De Bono, Neal D. Shore, Kim N. +18 more

Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients

European Urology Oncology(2024)10.1016/j.euo.2023.12.012

N/A

0DataRank · unranked

12 citations

Marta García de Herreros, Òscar Reig, Mercedes Marín‐Aguilera, Caterina Aversa, Laura Ferrer‐Mileo +21 more